AstraZeneca coronavirus vaccine registered 74 per cent efficacy at stopping vital diseases, according to the company’s US clinical trial results. The data was tested on over 26,000 volunteers in the US, Chile and Peru, who got two shots of the Covid-19 vaccine. The results were published in the New England Journal of Medicine.
- Choosing the best demat account in 2025
- People’s Bank of China Stops Bond Buying
- Nifty, Sensex Suffer Biggest Weekly Loss in a Month Due to Persistent FII Selling
- Canada-Based Startup Launches North
- Economy of India Set to Grow 6.6% in 2025
“I was stunned,” Dr Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the investigators, said of the overall result. “It was also very protective against serious disease and hospitalisation,” she said. AstraZeneca has said in July that it is planning to file full approval with the US Food and Drug Administration (FDA) rather than ask for emergency use authorisation. The company is also examining booster doses for people who have already been fully vaccinated.
